195 related articles for article (PubMed ID: 24232941)
1. [Signs and symptoms of ocular surface disease in patients on topical intraocular pressure-lowering therapy].
Gomes B; Turiel PR; Marques FP; Bernardo FP; Safady MV; Portes AL; Santhiago MR
Arq Bras Oftalmol; 2013 Oct; 76(5):282-7. PubMed ID: 24232941
[TBL] [Abstract][Full Text] [Related]
2. Ocular Surface Disease in Patients under Topical Treatment for Glaucoma.
Pérez-Bartolomé F; Martínez-de-la-Casa JM; Arriola-Villalobos P; Fernández-Pérez C; Polo V; García-Feijoó J
Eur J Ophthalmol; 2017 Nov; 27(6):694-704. PubMed ID: 28497458
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications.
Fechtner RD; Godfrey DG; Budenz D; Stewart JA; Stewart WC; Jasek MC
Cornea; 2010 Jun; 29(6):618-21. PubMed ID: 20386433
[TBL] [Abstract][Full Text] [Related]
4. Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study.
Saade CE; Lari HB; Berezina TL; Fechtner RD; Khouri AS
Can J Ophthalmol; 2015 Apr; 50(2):132-6. PubMed ID: 25863853
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.
García-López A; Paczka JA; Jiménez-Román J; Hartleben C
BMC Ophthalmol; 2014 Dec; 14():161. PubMed ID: 25527295
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of ocular surface complaints in Brazilian patients with glaucoma or ocular hypertension.
Costa VP; Marcon IM; Galvão Filho RP; Malta RF
Arq Bras Oftalmol; 2013; 76(4):221-5. PubMed ID: 24061832
[TBL] [Abstract][Full Text] [Related]
7. Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study.
Rolle T; Spinetta R; Nuzzi R
BMC Ophthalmol; 2017 Aug; 17(1):136. PubMed ID: 28768500
[TBL] [Abstract][Full Text] [Related]
8. Ocular surface disease and glaucoma: how to evaluate impact on quality of life.
Rossi GC; Pasinetti GM; Scudeller L; Bianchi PE
J Ocul Pharmacol Ther; 2013 May; 29(4):390-4. PubMed ID: 23215770
[TBL] [Abstract][Full Text] [Related]
9. High Prevalence of Ocular Surface Disease Among Glaucoma Patients in Thailand.
Ruangvaravate N; Prabhasawat P; Vachirasakchai V; Tantimala R
J Ocul Pharmacol Ther; 2018 Jun; 34(5):387-394. PubMed ID: 29596033
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of ocular surface disease in glaucoma patients.
Leung EW; Medeiros FA; Weinreb RN
J Glaucoma; 2008 Aug; 17(5):350-5. PubMed ID: 18703943
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Sezgin Akçay Bİ; Güney E; Bozkurt KT; Unlü C; Akçali G
J Ocul Pharmacol Ther; 2013 Dec; 29(10):882-6. PubMed ID: 24180628
[TBL] [Abstract][Full Text] [Related]
12. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Michaud JE; Friren B;
Am J Ophthalmol; 2001 Aug; 132(2):235-43. PubMed ID: 11476685
[TBL] [Abstract][Full Text] [Related]
13. Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension.
Thygesen J; Aaen K; Theodorsen F; Kessing SV; Prause JU
Acta Ophthalmol Scand; 2000 Feb; 78(1):37-44. PubMed ID: 10726786
[TBL] [Abstract][Full Text] [Related]
14. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
Easthope SE; Perry CM
Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
[TBL] [Abstract][Full Text] [Related]
15. Risk factors to develop ocular surface disease
in treated glaucoma or ocular hypertension patients.
Rossi GC; Pasinetti GM; Scudeller L; Raimondi M; Lanteri S; Bianchi PE
Eur J Ophthalmol; 2013; 23(3):296-302. PubMed ID: 23335308
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of ocular surface disease in patients with glaucoma.
Mathews PM; Ramulu PY; Friedman DS; Utine CA; Akpek EK
Ophthalmology; 2013 Nov; 120(11):2241-8. PubMed ID: 23714318
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the ocular hypotensive effects of bimatoprost and timolol-dorzolamide combination in patients with elevated intraocular pressure: a 6-month study.
Ozturk F; Ermis SS; Inan UU
Acta Ophthalmol Scand; 2007 Feb; 85(1):80-3. PubMed ID: 17244215
[TBL] [Abstract][Full Text] [Related]
18. Intraocular light scatter in patients on topical intraocular pressure-lowering medication.
Pérez-Bartolomé F; Martínez de la Casa JM; Arriola-Villalobos P; Fernández-Pérez C; García-Feijoó J
Eur J Ophthalmol; 2018 Nov; 28(6):652-661. PubMed ID: 29631441
[TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
[TBL] [Abstract][Full Text] [Related]
20. Symptoms and signs of tear film dysfunction in glaucomatous patients.
Valente C; Iester M; Corsi E; Rolando M
J Ocul Pharmacol Ther; 2011 Jun; 27(3):281-5. PubMed ID: 21557633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
